Financials in GBp. Standardized financial statements.
A compact view of how SkinBioTherapeutics Plc turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £4.64M | £1.21M | £132,057 | £74,761 | £0 | £0 | £0 | £0 | £0 | £2,769 |
| Revenue Growth? | +283.6% | +815.5% | +76.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% |
| Cost of Revenue? | £1.93M | £525,631 | £46,867 | £29,424 | £5,055 | £5,100 | £3,400 | £0 | £0 | £0 |
| Gross Profit? | £2.71M | £683,038 | £85,190 | £45,337 | -£5,055 | -£5,100 | -£3,400 | £0 | £0 | £2,769 |
| Gross Margin? | +58.3% | +56.5% | +64.5% | +60.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +100.0% |
| Operating Expenses? | £3.53M | £3.59M | £3.08M | £3.03M | £1.49M | £1.61M | £1.35M | £941,190 | £418,537 | £4,201 |
| Operating Income? | -£826,786 | -£2.90M | -£3.00M | -£2.98M | -£1.49M | -£1.62M | -£1.36M | -£941,000 | -£673,000 | -£4,201 |
| EBITDA? | -£196,540 | -£2.72M | -£2.96M | -£2.95M | -£1.49M | -£1.61M | -£1.36M | £0 | -£169,000 | -£323 |
| Income Before Tax | -£715,116 | -£2.95M | -£3.01M | -£2.99M | -£1.50M | -£1.62M | -£1.36M | -£941,000 | -£688,000 | -£4,201 |
| Income Tax Expense | -£18,863 | -£72,902 | -£173,089 | -£199,622 | -£65,065 | -£120,000 | -£212,000 | -£97,033 | -£42,685 | £0 |
| Net Income? | -£696,253 | -£2.88M | -£2.84M | -£2.79M | -£1.43M | -£1.50M | -£1.15M | -£844,000 | -£646,000 | -£4,201 |
| EPS? | £-0.00 | £-0.02 | £-0.02 | £-0.02 | £-0.01 | £-0.01 | £-0.01 | £-0.01 | £-0.01 | £-0.00 |
| Diluted EPS? | £-0.00 | £-0.02 | £-0.02 | £-0.02 | £-0.01 | £-0.01 | £-0.01 | £-0.01 | £-0.01 | £-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality